

## Pectolarigenin Datasheet

4<sup>th</sup> Edition (Revised in July, 2016)

### [ Product Information ]

**Name:** Pectolarigenin

**Catalog No.:** CFN99010

**Cas No.:** 520-12-7


**Purity:** > 98%

**M.F:** C<sub>17</sub>H<sub>14</sub>O<sub>6</sub>

**M.W:** 314.3

**Physical Description:** Yellow powder

**Synonyms:** 5,7-Dihydroxy-6-methoxy-2-(4-methoxyphenyl)-1-benzopyran-4-one.



### [ Intended Use ]

1. Reference standards;
2. Pharmacological research;
3. Synthetic precursor compounds;
4. Intermediates & Fine Chemicals;
5. Others.

### [ Source ]

The leaves of *Linaria vulgaris* Mill.

### [ Biological Activity or Inhibitors ]

Pectolinarin and pectolinarigenin exhibit hepatoprotective activity mainly via SOD antioxidant mechanism, can prevent the hepatic injury in rats caused by D-galactosamine.<sup>[1]</sup>

Pectolinarigenin and pectolinarin possess anti-inflammatory activity and that they may inhibit eicosanoid formation in inflammatory lesions. <sup>[2]</sup>

Pectolinarigenin inhibits breast cancer stem cell-like properties and lowers the chemoresistance of the cancer cells to chemotherapy, the results provide an insight into the mechanism of the anti-breast tumor effects and an experimental basis for the use of pectolinarigenin to enhance treatment of patients with breast cancer.<sup>[3]</sup>

Pectolinarigenin shows potent anti-proliferation activity by inducing apoptosis and downregulation of Bcl2 expression in MCF-7 breast cancer cell; protein expression of Bcl2 is almost completely inhibited upon the treatment with 25 mM pectolinarigenin. <sup>[4]</sup>

## **[ Solvent ]**

Chloroform, Dichloromethane, DMSO, Acetone, etc.

## **[ HPLC Method ]<sup>[5]</sup>**

Mobile phase: Acetonitrile- 0.1% Ortho phosphoric acid H<sub>2</sub>O, gradient elution ;

Flow rate: 1.0 ml/min;

Column temperature: Room Temperature;

The wave length of determination: 331 nm.

## **[ Storage ]**

2-8°C, Protected from air and light, refrigerate or freeze.

## **[ References ]**

[1] Yoo Y M, Nam J H, Kim M Y, *et al. Biol. Pharm. Bull.*, 2008, 31(4):760-4.

[2] Lim H, Son K H, Chang H W, *et al. Biol. Pharm. Bull.*, 2008, 31(11):2063-7.

[3] Lu M, Xu X, Lu H, *et al. Trop. J. Pharm. Res.*, 2016, 15(3):547-53.

[4] Lu M, Kong Q, Xu X, *et al. Trop. J. Pharm. Res.*, 2014, 13(2):225-8.

[5] Sakpakdeejaroen I, Juckmeta T, Itharat A. *J. Med. Assoc. Thai.* 2014 ;97(8):S76-80.

## **[ Contact ]**

**Address:**

S5-3 Building, No. 111, Dongfeng Rd.,  
Wuhan Economic and Technological Development Zone,  
Wuhan, Hubei 430056,  
China

**Email:** [info@chemfaces.com](mailto:info@chemfaces.com)

**Tel:** +86-27-84237783

**Fax:** +86-27-84254680

**Web:** [www.chemfaces.com](http://www.chemfaces.com)

**Tech Support:** [service@chemfaces.com](mailto:service@chemfaces.com)